Trust Co. of Vermont Raises Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Trust Co. of Vermont increased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 5,049 shares of the medical equipment provider’s stock after acquiring an additional 410 shares during the period. Trust Co. of Vermont’s holdings in Intuitive Surgical were worth $2,246,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after acquiring an additional 272,741 shares in the last quarter. Capital World Investors raised its stake in shares of Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after acquiring an additional 73,634 shares in the last quarter. Edgewood Management LLC raised its stake in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after acquiring an additional 374,667 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after acquiring an additional 88,977 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ISRG has been the topic of a number of analyst reports. Truist Financial raised their price target on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Robert W. Baird raised their price target on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Citigroup raised their price target on Intuitive Surgical from $462.00 to $512.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Stifel Nicolaus raised their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Finally, Barclays raised their price target on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $442.30.

Intuitive Surgical Price Performance

Shares of ISRG stock traded up $9.66 during midday trading on Tuesday, reaching $447.66. 1,662,729 shares of the company traded hands, compared to its average volume of 1,573,488. The firm’s 50 day simple moving average is $432.79 and its two-hundred day simple moving average is $402.15. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $468.78. The firm has a market cap of $158.79 billion, a PE ratio of 80.81, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm earned $1.18 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $385.55, for a total transaction of $92,146.45. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,123,223.85. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Robert Desantis sold 239 shares of Intuitive Surgical stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $385.55, for a total transaction of $92,146.45. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,123,223.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $1,291,010.34. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at $136,522.74. The disclosure for this sale can be found here. In the last three months, insiders sold 16,005 shares of company stock worth $6,894,422. Company insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.